Iambic prices IPO at $16 a share, raising $150.0 million on Nasdaq

Offering terms and timeline

According to the company's announcement, all of the shares are being offered by Iambic itself. The $150.0 million in expected gross proceeds is calculated before underwriting discounts and commissions and other offering expenses payable by the company.

Iambic has also granted the underwriters a 30-day option to buy up to an additional 1,406,250 shares at the initial public offering price, less underwriting discounts and commissions.

The common stock is expected to begin trading on the Nasdaq Global Select Market on October 15, 2026, under the ticker symbol "IAM." The offering is expected to close on October 16, 2026, subject to customary closing conditions.

J.P. Morgan, Jefferies, BofA Securities and Citigroup are acting as joint book-running managers. A registration statement was filed with the Securities and Exchange Commission and became effective on October 14, 2026. The offering is made only by means of a prospectus, and the final prospectus will be available at www.sec.gov when ready. The company also said the preliminary prospectus was included in a Form S-1 filed with the SEC on October 8, 2026.

What Iambic does

Iambic, based in San Diego, describes itself as a clinical-stage life sciences and technology company advancing novel medicines with an AI-driven platform. Its stated mission is to make "better technology for better medicines."

The company says its platform uses what it calls molecular superintelligence, which integrates proprietary AI with automated, scalable chemistry and biology experimentation. According to Iambic, the platform is designed to address the totality of drug discovery and development.

As evidence of the platform's utility, the company points to IAM1363, a novel drug candidate that it says advanced to the clinic in approximately two years. Iambic also reports a diverse preclinical pipeline. Its leading AI technologies are named as Enchant and NeuralPLexer, which are designed for multimodal endpoint prediction to improve the speed, precision and success rates of drug discovery and clinical development.

Recent company news and what it means

The listing follows two announcements the company published on September 21, 2026: the launch of Enchant v3, which Iambic describes as molecular superintelligence designed to advance end-to-end drug discovery and development, and a collaboration with AbbVie to accelerate AI-driven drug discovery. The source gives no further detail on either item.

For the market, the pricing marks the arrival of another AI-focused drug discovery company as a publicly traded firm. The announcement itself does not include financial results, use-of-proceeds details or clinical data, so those points are left to the prospectus. The release also carries standard forward-looking statement warnings, noting that actual results may differ materially from expectations and that risks are described in the preliminary prospectus.